PARIS–(COMMERCIAL THREAD) – Regulatory news:

Ikonisys SA (ISIN code: FR00140048X2 / Ticker: ALIKO), company specializing in the early and accurate detection of cancer with a unique fully automated solution for medical analysis laboratories, today announced its financial results for the first half of the fiscal year ended June 30, 2021 and provides an update on its activity and its development prospects.

Mario Crovetto, CEO of Ikonisys, said: “The first half of 2021 was marked by the completion of the development of Ikoniscope20 and the preparation for our IPO, which then took place in July. Thanks to this transaction, we strengthened our financial capacities and were able to accelerate our development by recruiting a sales manager for the United States. These efforts will continue in order to strengthen our teams also in Europe and to support the marketing of the latest generation ikoniscope20 platform. Our platform offers fluorescence in situ hybridization (FISH) -based diagnostic assays, primarily in the oncology segment of molecular diagnostics, an important market in which we aim to become one of the world’s leading suppliers. This ambition is supported by the differentiating characteristics of our fully automated solution, capable of detecting rare cells with great reliability.Our strong technological characteristics allow us to also target the promising market of c analysis of circulating tumor cells (CTC) by liquid biopsy. , a breakthrough in the field of diagnostics. These promising business prospects, combined with the strengthening of our sales force and the pursuit of our R&D efforts, in particular concerning the integration of advanced AI technologies into our platform, ideally position Ikonisys to continue its development.

Half-year results 2021 as of June 30, 2021 / Simplified income statement

euros

S1 2021

H1 2020

Income

238 643

313 728

COGS

– 8 890

– 4,703

Operating Expenses

338 514

156,029

Operating profit / (loss)

(108,761)

152,997

Financial income / (losses)

(4,435)

(917 214)

Extraordinary income / (loss)

Net profit / (loss)

(113,196)

(764,217)

Details of the main changes in the pro forma combined accounts

The cumulative turnover for the period ended June 30, 2021 amounts to 0.24 million euros and comes mainly from the service maintenance contracts stipulated between Ikonisys Inc and historical customers still using the first generation instrument. .

Compared to the same period of the previous fiscal year, there was a slight decrease of € 66,019 in revenue which was expected due to the pandemic situation and the related change in the workflow in the laboratories that had to do facing a high number of Covid-19 tests, limiting their ability to perform other tests, namely FISH tests.

As a result of the restructuring of the company that took place before the IPO in May 2021, interest charges were significantly reduced, positively affecting the bottom line.

Following the same restructuring, Ikonisys Srl, i.e. the Italian subsidiary of Ikonisys SA, controls 100% of Ikonisys Inc (the American subsidiary) on June 30, 2021. Under IFRS 10, consolidated financial statements have therefore been prepared for these two subsidiaries.

Highlights after closing

  • Ikonisys successful IPO at Euronext Growth® Paris

    The IPO resulted in a capital increase of 4.0 million euros through the issuance of 700,000 new ordinary shares.
  • First study results demonstrate the ability of the Ikoniscope20 rare cell detection platform to enumerate specific populations of CD8 T cells

    Using the high-speed scanning of the Ikoniscope20 platform, 80 extremely rare antigen-specific CD8 T cells from over one million blood cells were identified. Antigen-specific T cells play a central role in immunity against cancers and infectious agents through their ability to kill malignant cells upon recognition by the T cell receptor. This is further demonstration , in collaboration with the Faculty of Medicine of the University of Connecticut (USA), of the potential of Ikonisys technology in immuno-oncology thanks to its ability to detect rare cells in general, and circulating tumor cells in particular.
  • Recruitment of Manny Iglesias as Commercial Director for the US market

    Manny Iglesias will be responsible for accelerating Ikoniscope20 sales in the United States by strengthening the Company’s presence in new geographies of the United States while optimizing the marketing and sales strategy. Manny’s business leadership and extensive experience in building strong customer relationships will support the accelerated growth of Ikonisys.

Strategy and outlook

In the coming months, the Company intends to accelerate the development of its strategy announced at the time of the IPO, in particular the marketing of the Ikoniscope20 platform in the United States and in Europe by capitalizing on the strengthening of its sales force and its and future partnerships with prestigious clinical, academic and private laboratories. Ikonisys will also continue its R&D efforts to enrich the ikoniscope20 platform and integrate artificial intelligence technologies.

Next financial press release: April 22, 2022

About Ikonisys

Ikonisys SA is a cellular diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specializing in the early and precise detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully automated solution designed to provide accurate and reliable detection and analysis of rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its revolutionary fluorescence microscopy platform, the company continues to develop a stream of new assays, including liquid biopsy assays based on circulating tumor cells (CTC).

For more information, visit www.Ikonisys.com.

Disclaimer

This press release contains forward-looking statements on the prospects and development of the Company. These statements are sometimes identified by the use of the future, the conditional and forward-looking words such as “believe”, “aim at”, “expect”, “intend”, “estimate”, “believe”. “,” Should, “” could “,” would “or” will “or, as the case may be, the negative of these terms or any other variation or similar expression. This information is not historical data and should not be interpreted as a guarantee that the facts and data presented will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is likely to evolve or change due to uncertainties related to the economic, financial, competitive and regulatory environment This information contains data relating to the intentions, estimates and objectives of the Company, in particular with regard to the market, strategy, growth, results, financial situation and tr Company cash flow. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all the risks, uncertainties or other factors that may affect its activities, their potential impact on its activities or the extent to which the materialization of a risk or a combination of risks could lead to results that are materially different from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.